LVGN6051 + pembrolizumab

LVGN6051 + pembrolizumab is a combination therapy consisting of LVGN6051, a conditional 4-1BB (CD137) agonistic monoclonal antibody with Fc-γ receptor IIB selective binding designed for selective activation in the tumor microenvironment, and pembrolizumab (Keytruda), an anti-PD-1 antibody. This combination aims to enhance anti-tumor immune responses by targeting complementary immune pathways. LVGN6051 provides critical support for CD8+ effector T cells in a manner that complements PD-1 blockade by pembrolizumab. The recommended Phase 2 dose (RP2D) for the combination was established as LVGN6051 4 mg/kg and pembrolizumab 200 mg IV administered every three weeks (Q3W).